Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (1086/15)
13/04/2016
Indication
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously untreated with ipilimumab.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
50mg powder for concentrate for solution for infusion
Comments
April 2016 - Included on the Additional List, Specialist Use only, for the indication in question.